---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274314"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:36:58.599910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProKidney reports Q3 net loss $35.8M, cash $271.7M; Phase 3 PROACT 1 enrollment >50%, topline Q2 2027

## Summary
- Q3 net loss before noncontrolling interest $35.8M vs $41.1M YoY; R&D expenses $26.8M.
- Cash and equivalents $271.7M, expected to fund operations into mid-2027.
- Phase 3 PROACT 1 accelerated approval analysis: >50% of ~360 patients enrolled, topline results Q2 2027.
- FDA confirmed eGFR slope as surrogate endpoint for BLA under accelerated approval; RMAT designation continues.
- Phase 2 REGEN-007 data at ASN: 78% improvement in eGFR decline (p<0.001); well tolerated.

## SEC filing metadata
- accession: 0001193125-25-274314
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000119312525274314/0001193125-25-274314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000119312525274314/prok-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274314
- JSON: https://secwatch.observer/filing/0001193125-25-274314.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.